Scilex Holding

0.28
-0.00 (-0.04%)
At close: Mar 24, 2025, 3:59 PM
0.28
0.94%
After-hours: Mar 24, 2025, 07:52 PM EDT
-0.04%
Bid 0.27
Market Cap 67.5M
Revenue (ttm) 105.69M
Net Income (ttm) -168.16M
EPS (ttm) -0.81
PE Ratio (ttm) -0.34
Forward PE -1.48
Analyst Buy
Ask 0.29
Volume 926,317
Avg. Volume (20D) 1,432,800
Open 0.28
Previous Close 0.28
Day's Range 0.26 - 0.29
52-Week Range 0.21 - 2.30
Beta 1.16

About SCLX

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural i...

Sector Healthcare
IPO Date Mar 5, 2021
Employees 117
Stock Exchange NASDAQ
Ticker Symbol SCLX
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for SCLX stock is "Buy." The 12-month stock price forecast is $13.5, which is an increase of 4766.62% from the latest price.

Stock Forecasts
1 month ago
-6.39%
Scilex shares are trading lower after the company ... Unlock content with Pro Subscription
3 months ago
-12.75%
Scilex Holding shares are trading lower after the company announced a $17 million registered direct offering.